GSK3β-sparing DYRK1A kinase inhibitor

orally efficacious in proliferation model, but non-specific proliferation observed

from cellular phenotypic screen and opt.

J. Med. Chem. Feb. 20, 2020

Novartis (GNF), San Diego, CA

Structure of selective DYRK1A inhibitor GNF2133

GNF2133 (Novartis (GNF) oral in vivo GSK3-beta-sparing DYRK1A kinase inhibitor)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: